Purging with Chlorambucil to prevent infusion-related reactions before Obinutuzumab administration: a monocentric pilot experience.

08:00 EDT 11th October 2019 | BioPortfolio

Summary of "Purging with Chlorambucil to prevent infusion-related reactions before Obinutuzumab administration: a monocentric pilot experience."

Obinutuzumab-Chlorambucil (Chl-G) combination in untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities, has proven to be safe and more effective than other treatments in the CLL11 study. The Chl dose used in CLL11 was lower than its use in associations with Rituximab in other European experiences; moreover, has emerged that the infusion of G is burdened by a high incidence of infusion-related reactions (IRRs). Given the previous experience of our group, we used, in the same setting of pts of the CLL11, a 2-cycle purging dose of Chl in association with G looking at safety and response, to prevent the occurrence of these adverse events (AE). We retrospectively analysed a pilot cohort of 10 untreated CLL pts with comorbidities, treated with G-Chl regimen. At 2 months after the end of the therapy the overall response rate was 80%. In the safety analysis, grade 3-4 treatment-emergent AE occurred in 50% of pts, but no grade 3-4 IRRs or clinical tumor lysis syndrome have been detected in our cohort. When comparing CBCs before and after the first 2 cycles of Chl, we observed a statistically significant reduction of lymphocytes from a mean of 50.310x10^9/l to 15.710x10^9/l (p=0.034), while no significant differences were detected in haemoglobin levels, neutrophil and platelet counts. Median dose of Chl used was 520 mg for each patient (210-640 mg) with median Chl of 78 mg for each cycle. Our real-life pilot analysis suggests that the use of a Chl purging regimen is a valid option to minimize the IRR, since no grade 3-4 were observed. Toxicities and response rates were like already published experiences. These results are encouraging, but further studies with wider cohorts are needed to confirm them.


Journal Details

This article was published in the following journal.

Name: Hematological oncology
ISSN: 1099-1069


DeepDyve research library

PubMed Articles [14940 Associated PubMed Articles listed on BioPortfolio]

Incidence and Management of Olaratumab Infusion-Related Reactions.

Olaratumab is a human monoclonal immunoglobulin G1 antibody against platelet-derived growth factor receptor-α. We report the nature and frequency of infusion-related reactions (IRRs) with olaratumab ...

Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.

The increasing use in the last decade of PEGylated nanodrugs such as Doxil® has seen a rise in the number of associated occurrences of hypersensitivity reactions (HSRs). These reactions)also called i...

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

This study analyzed 91 multiple myeloma patients who received two monoclonal antibodies, Daratumumab and Elotuzumab, over a year and report the adverse event profile, infusion practices and utilizatio...

Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs.

Intravenous administration of liposomal drugs can entail infusion reactions, also known as hypersensitivity reactions (HSRs), that can be severe and sometimes life-threatening in a small portion of pa...

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase.

The aim of this work is to evaluate the impact of the timing of pre-infusion serum uric acid (sUA) test results for use in applying stopping rules for pegloticase to identify patients at risk for infu...

Clinical Trials [8044 Associated Clinical Trials listed on BioPortfolio]

CLL11: A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

This open-label, randomized, 3-arm study will evaluate the efficacy and safety of RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alon...

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Aim of the study is to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to C...

A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have s...

Gazyva Infusion Reaction Investigation

The study evaluate safety and effectiveness of chlorambucil and obinutuzumab in routine clinical practice in patients with chronic lymphatic leukemia and with certain comorbidities (any ca...

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which chlorambucil regimen is more effective in...

Medical and Biotech [MESH] Definitions

Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.

An eating disorder that is characterized by a cycle of binge eating (BULIMIA or bingeing) followed by inappropriate acts (purging) to avert weight gain. Purging methods often include self-induced VOMITING, use of LAXATIVES or DIURETICS, excessive exercise, and FASTING.

Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.

A rare but serious transfusion-related reaction in which fluid builds up in the lungs unrelated to excessively high infusion rate and/or volume (TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD). Signs of Transfusion-Related Acute Lung Injury include pulmonary secretions; hypotension; fever; DYSPNEA; TACHYPNEA; TACHYCARDIA; and CYANOSIS.

Use of any infusion therapy on an ambulatory, outpatient, or other non-institutionalized basis.

Quick Search

DeepDyve research library

Relevant Topic

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Searches Linking to this Article